



design your clinical trials intelligently

Kim Walpole | CEO/Co-Founder | +1 518-424-2283 | www.trials.ai

Problem for life science companies

43%

of clinical trials fail due to
poorly designed protocols

BILLION\$


are squandered in **preventable** mistakes



Companies lose
money and patients
don't have time to
wait

Our Smart Protocol Designer uses AI to automate today's manual processes:

- 🧩 Predict costly protocol changes (amendments)
- 🧩 Recommend best recruitment & retention strategies
- 🧩 Optimize testing & treatments for speed & cost



Use Case



When running a phase 1 study I need to know when to collect blood samples to accurately describe drug activity:

- AUC, C_{max}, T_{max}, T_½

Consequences for getting it wrong

- ✚ Insufficient blood samples could lead to a failed trial
- ✚ Unnecessary sampling adds risk and complexity - hard to recruit and retain patients
- ✚ Blood samples cost¹ between \$130 and \$300 each

Retrospective

This trial collected blood samples at 15 different time points¹

¹ View study [here](#)

https://clinicaltrials.gov/ct2/show/NCT02011633

NIH U.S. National Library of Medicine
ClinicalTrials.gov

Find Studies ▾ About Studies ▾ Submit Studies ▾ Resources ▾ About Site ▾

Home > Search Results > Study Record Detail Save this study

Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg

⚠ The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT02011633

Recruitment Status ⓘ: Completed
First Posted ⓘ: December 13, 2013
Last Update Posted ⓘ: March 11, 2014

Sponsor:
Hanmi Pharmaceutical Company Limited

Information provided by (Responsible Party):
Hanmi Pharmaceutical Company Limited

Study Details Tabular View No Results Posted Disclaimer ? How to Read a Study Record

Study Description

Go to ▾


Brief Summary:
To compare the pharmacokinetic characteristics between HCP1201 tablet 500/10 mg and co-administration of metformin 500 mg plus rosuvastatin 10 mg under fasted and fed state, respectively.

Condition or disease ⓘ	Intervention/treatment ⓘ	Phase ⓘ
Diabetes Mellitus	Drug: HCP1201 500/10mg Drug: Metformin SR 500mg Drug: Rosuvastatin 10mg	Phase 1

Detailed Description:
An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 500/10 mg and Coadministration of Metformin SR 500 mg and Rosuvastatin

Looking across 100 similar diabetes studies Trials.ai identified 10 optimal blood sampling time points

Type 2 Diabetes PK Sampling Time Points



Cost savings

Trials.ai would have recommended:

🌀 1/3 reduction in their sampling timepoints

= 5 less samples per patient or 360 total

= \$108k reduction in lab tests alone

Time & Cost Savings


If that reduction in 360 samples (\$108k savings)
led to 10 less patient dropouts (\$38.5k per)
and 1 less protocol change/amendment (61 days delayed)

SAVINGS = 2 MONTHS & \$500k

Data-driven protocol decisions

Public & Customer Data

- Synopsis/Protocols
- Clinical Study Reports
- Medical Journals
- Clinical Data
- KOL articles
- Regulatory Bodies
- Drug Labels



Global market opportunity

\$65.2 Billion
clinical trial market

\$3.7 Billion
addressable
market

\$5 Billion
total protocol design
opportunity

Differentiator: Power in the hands of researchers


clinical trial services | manual

technology platform

therapeutic area
agnostic



therapeutic area
focus

 Many companies offer products that span across categories. To keep the map simple, the logo is in the "primary" product. *Have an update? Leave a comment in the Medium post.*

Software-Enabled Clinical Trials

Trial Administration

Patient-Level Data Collection

Protocol design and review



VITAL CROWD

ProofPilot

trials.ai

HealthVibe

+ AllTrials

0



Site Selection & Start-Up¹



Patient Recruitment



Operational Management²



Drug & Supply Logistics



Patient and Outcome Data Management³



Digital Biomarker Collection⁴



Virtual Trials

Science 37

MEDABLE



CLINPAL

THREAD

aparito

EmpiraMed



monARC BIONETWORKS



0 Unlike the other for-profit ventures on this map, CTTI is a Public-Private partnership & AllTrials is a registered charity

1 Includes startup tools like eConsent and site training

2 Includes clinical trial management systems, risk-based monitoring, site monitoring, payment automation

3 Includes EDC (electronic data capture), eCOA (Electronic Clinical Outcomes Assessment), and ePRO (electronic Patient Reported Outcome)

4 Includes clinically-validated sensors



Subscription Model

Pharma | Biotech | Devices

Inbound Sales:

- Tier 1 Pharma:
 - 9-18 month sales cycle
- Inbound Small/Med sized CRO's:
 - 6-12 month sales cycle

Direct Outbound Sales:

- Biotech & Pharma
- 3 – 6 month sales cycle

PAY AS YOU GO

per active trial
running under 10 trials

ENTERPRISE PRICING

Running 10 or more
trials per year

Solid mix of passion and experience



Kim Walpole

CEO

*12+ years Pharma
Consulting*



Dr. David Fogel

Chief Scientist

*Research Scientist
& AI Pioneer*



Tom Walpole

CTO

*HIPAA Compliant
Scalable Systems*



Josh Stanley

Product

*Product Strategy &
Prioritization*



Genentech



MERCK



NOVARTIS

AMGEN



IEEE
Computational
Intelligence
Society

trials.ai

Advisors are industry experts



Andreas Koester, MD, PhD

Global Head of Clinical
Innovation



Iqbal Hussein, MD

Worldwide Medical Director



Stephen Jenkins, MD

VP Clinical Research



Tom Giles

Business Development
Manager



We get things done

Went to market and tested our hypothesis:

- Built & sold initial trial execution platform to small players
- Learned that greatest opportunity is in Protocol Design
- Reset the business to focus on Protocol Design

We get things done

Developed our Protocol Design Product:

- Patent Pending on our Patient Burden Index TM
- Data processing pipeline
- Clinical Trials Ontology
- Recommendation Algorithms
- Built out our API

We get things done

Resulting in Traction with \$7.6M Sales Pipeline (weighted):

- In contract negotiations with 3 of the top 10 Big Pharma companies
- 1 CRO (consultant) proposal - 3 year contract
- Currently generating revenue

Raise & milestones

- Focus on direct sales to build immediate revenue
- Expand platform capabilities
- \$3M ARR by Q4 2019

\$300k available

\$750k Note

\$5M CAP

20% discount


5% interest



Kim Walpole
CEO & Co-Founder



U.S.A.
1510 Front St, 400
San Diego, CA 92101



+1-518-314-9413



kim@trials.ai



www.trials.ai